143 related articles for article (PubMed ID: 12761038)
1. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy.
Lesbordes JC; Cifuentes-Diaz C; Miroglio A; Joshi V; Bordet T; Kahn A; Melki J
Hum Mol Genet; 2003 Jun; 12(11):1233-9. PubMed ID: 12761038
[TBL] [Abstract][Full Text] [Related]
2. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model.
Haddad H; Cifuentes-Diaz C; Miroglio A; Roblot N; Joshi V; Melki J
Muscle Nerve; 2003 Oct; 28(4):432-7. PubMed ID: 14506714
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model.
Cifuentes-Diaz C; Nicole S; Velasco ME; Borra-Cebrian C; Panozzo C; Frugier T; Millet G; Roblot N; Joshi V; Melki J
Hum Mol Genet; 2002 Jun; 11(12):1439-47. PubMed ID: 12023986
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice.
Bordet T; Lesbordes JC; Rouhani S; Castelnau-Ptakhine L; Schmalbruch H; Haase G; Kahn A
Hum Mol Genet; 2001 Sep; 10(18):1925-33. PubMed ID: 11555629
[TBL] [Abstract][Full Text] [Related]
5. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy.
Little D; Valori CF; Mutsaers CA; Bennett EJ; Wyles M; Sharrack B; Shaw PJ; Gillingwater TH; Azzouz M; Ning K
Mol Ther; 2015 Feb; 23(2):270-7. PubMed ID: 25369768
[TBL] [Abstract][Full Text] [Related]
6. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
[TBL] [Abstract][Full Text] [Related]
7. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.
Passini MA; Bu J; Roskelley EM; Richards AM; Sardi SP; O'Riordan CR; Klinger KW; Shihabuddin LS; Cheng SH
J Clin Invest; 2010 Apr; 120(4):1253-64. PubMed ID: 20234094
[TBL] [Abstract][Full Text] [Related]
8. Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides.
Lin TL; Chen TH; Hsu YY; Cheng YH; Juang BT; Jong YJ
PLoS One; 2016; 11(4):e0154723. PubMed ID: 27124114
[TBL] [Abstract][Full Text] [Related]
9. A large animal model of spinal muscular atrophy and correction of phenotype.
Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
[TBL] [Abstract][Full Text] [Related]
10. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.
Monani UR; Pastore MT; Gavrilina TO; Jablonka S; Le TT; Andreassi C; DiCocco JM; Lorson C; Androphy EJ; Sendtner M; Podell M; Burghes AH
J Cell Biol; 2003 Jan; 160(1):41-52. PubMed ID: 12515823
[TBL] [Abstract][Full Text] [Related]
11. Defining the therapeutic window in a severe animal model of spinal muscular atrophy.
Robbins KL; Glascock JJ; Osman EY; Miller MR; Lorson CL
Hum Mol Genet; 2014 Sep; 23(17):4559-68. PubMed ID: 24722206
[TBL] [Abstract][Full Text] [Related]
12. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
Tseng YT; Chen CS; Jong YJ; Chang FR; Lo YC
Pharmacol Res; 2016 Sep; 111():58-75. PubMed ID: 27241020
[TBL] [Abstract][Full Text] [Related]
13. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.
Benkhelifa-Ziyyat S; Besse A; Roda M; Duque S; Astord S; Carcenac R; Marais T; Barkats M
Mol Ther; 2013 Feb; 21(2):282-90. PubMed ID: 23295949
[TBL] [Abstract][Full Text] [Related]
16. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy.
Cifuentes-Diaz C; Frugier T; Tiziano FD; Lacène E; Roblot N; Joshi V; Moreau MH; Melki J
J Cell Biol; 2001 Mar; 152(5):1107-14. PubMed ID: 11238465
[TBL] [Abstract][Full Text] [Related]
17. AAV9-DOK7 gene therapy reduces disease severity in Smn
Kaifer KA; Villalón E; Smith CE; Simon ME; Marquez J; Hopkins AE; Morcos TI; Lorson CL
Biochem Biophys Res Commun; 2020 Sep; 530(1):107-114. PubMed ID: 32828271
[TBL] [Abstract][Full Text] [Related]
18. Defects in neuromuscular junction remodelling in the Smn(2B/-) mouse model of spinal muscular atrophy.
Murray LM; Beauvais A; Bhanot K; Kothary R
Neurobiol Dis; 2013 Jan; 49():57-67. PubMed ID: 22960106
[TBL] [Abstract][Full Text] [Related]
19. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
20. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
